EP0647625A1 — Novel antibiotics with immunosuppressive activity, delaminomycins, and production thereof
Assigned to Microbial Chemistry Research Foundation · Expires 1995-04-12 · 31y expired
What this patent protects
Delaminomycins A, B and C, represented by general formula (I) or (I'), or salts thereof, delaminomycins A2, B2 and C2, represented by general formula (II), and sulfates of delaminomycins A2 to C2, represented by general formula (III), or salts thereof. The delaminomycins selectiv…
USPTO Abstract
Delaminomycins A, B and C, represented by general formula (I) or (I'), or salts thereof, delaminomycins A2, B2 and C2, represented by general formula (II), and sulfates of delaminomycins A2 to C2, represented by general formula (III), or salts thereof. The delaminomycins selectively inhibit T cells, have the activity of inhibiting the growth of certain cancer cells, and are antibacterial.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.